Show simple item record

dc.contributor.authorFoy, Victoria
dc.contributor.authorFernandez-Gutierrez, Fabiola
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorDive, Caroline
dc.contributor.authorBlackhall, Fiona H
dc.date.accessioned2017-10-18T20:53:35Z
dc.date.available2017-10-18T20:53:35Z
dc.date.issued2017-08
dc.identifier.citationThe clinical utility of circulating tumour cells in patients with small cell lung cancer. 2017, 6 (4):409-417 Transl Lung Cancer Resen
dc.identifier.issn2218-6751
dc.identifier.pmid28904885
dc.identifier.doi10.21037/tlcr.2017.07.05
dc.identifier.urihttp://hdl.handle.net/10541/620591
dc.description.abstractSmall cell lung cancer (SCLC) accounts for 15% of lung cancer diagnosed worldwide. It is aggressive and characterised by early metastatic spread with rapid development of chemo resistance such that less than 5% of patients diagnosed survive 5 years. Surgery is rarely performed and failure to identify new effective treatments has been attributed in a large part to lack of good quality tumour biopsies available for translational research. Liquid biopsies provide a minimally invasive alternative to traditional tumour biopsy. Circulating tumour cells (CTCs) are abundant in SCLC and can be enriched and isolated from a venous blood sample. In recent years progress has been made into the molecular characterisation of CTCs and their use to form tumour xenografts in mice for preclinical studies. This review will discuss the current status of the clinical utility of CTCs in patients with SCLC, highlighting their potential application to treatment decision making, drug development in clinical trials and preclinical testing.
dc.language.isoenen
dc.rightsArchived with thanks to Translational lung cancer researchen
dc.titleThe clinical utility of circulating tumour cells in patients with small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Pharmacology Group, CRUK Manchester Institute, CRUK Manchester Institute, University of Manchester, Manchesteren
dc.identifier.journalTranslational Lung Cancer Researchen
html.description.abstractSmall cell lung cancer (SCLC) accounts for 15% of lung cancer diagnosed worldwide. It is aggressive and characterised by early metastatic spread with rapid development of chemo resistance such that less than 5% of patients diagnosed survive 5 years. Surgery is rarely performed and failure to identify new effective treatments has been attributed in a large part to lack of good quality tumour biopsies available for translational research. Liquid biopsies provide a minimally invasive alternative to traditional tumour biopsy. Circulating tumour cells (CTCs) are abundant in SCLC and can be enriched and isolated from a venous blood sample. In recent years progress has been made into the molecular characterisation of CTCs and their use to form tumour xenografts in mice for preclinical studies. This review will discuss the current status of the clinical utility of CTCs in patients with SCLC, highlighting their potential application to treatment decision making, drug development in clinical trials and preclinical testing.


This item appears in the following Collection(s)

Show simple item record